Ilorasertib

Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) [1][2].

Product Specifications

CAS Number

[1227939-82-3]

Product Name Alternative

ABT-348

UNSPSC

12352005

Hazard Statement

H315, H317, H319, H335

Target

Aurora Kinase; PDGFR; VEGFR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ABT-348.html

Purity

99.86

Solubility

DMSO : 41.67 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=CC(F)=C1)NC2=CC=C(C3=CSC4=C3C(N)=NC=C4C5=CN(CCO)N=C5)C=C2

Molecular Formula

C25H21FN6O2S

Molecular Weight

488.54

Precautions

H315, H317, H319, H335

References & Citations

[1]Yi-Chun Wang, et al. Abstract 858: Potent in vivo activity of the aurora kinase inhibitor ABT-348 in human acute myeloid leukemia and myelodysplastic syndrome xenograft models. Cancer Res (2012) 72 (8_Supplement) : 858.|[2]Glaser KB, et al. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343 (3) :617-27.